<DOC>
	<DOCNO>NCT02545855</DOCNO>
	<brief_summary>This prospective , randomize crossover study evaluation efficacy safety long-term nocturnal high-flow nasal cannula therapy myAIRVO2® stable COPD patient stage 2-4 Global Initiative Chronic Obstructive Lung Disease ( GOLD ) hypercapnia require home oxygen therapy ( HOT ) . The total duration subject participation 52 week , consist 12-week treatment period 40-week continuation period . Subjects satisfy inclusion exclusion criterion randomly assign one two treatment arm , Arm A ( week 1-6 : myAIRVO2® therapy plus HOT , week 7-12 : HOT ) Arm B ( week 1-6 : HOT , week 7-12 : myAIRVO2® therapy plus HOT ) . All subject receive nocturnal high-flow nasal cannula therapy myAIRVO2® , addition current HOT . After treatment period , willing subject continue myAIRVO2® therapy plus HOT week 13-52 regardless treatment arm assignment . The end study define treatment period continuation period end date last participant , whichever later . Subjects primarily assess St. George 's Respiratory Questionnaire COPD Patients ( SGRQ-C ) week 0 , 6 , 12 , 24 52 .</brief_summary>
	<brief_title>High-flow Nasal Cannula Therapy Stable Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>1 . Subjects Global Initiative Obstructive Lung Disease ( GOLD ) stage 24 COPD 2 . Subjects receive HOT least 16 hour per day least 1 month time inform consent 3 . Subjects PaCO2 &lt; = 60 torr , &gt; = 45 torr time screen 4 . Subjects sign write informed consent participate study 1 . Subjects severe kidney , liver cardiovascular disease 2 . Subjects active malignant tumor 3 . Subjects acute disease ( i.e. , acute myocardial infarction ) 4 . Subjects history obstructive sleep apnea syndrome 5 . Subjects complication affect efficacy endpoint regard investigator inadequate study 6 . Subjects experience COPD exacerbation within past 6 week prior inform consent 7 . Subjects receive nocturnal noninvasive positive pressure ventilation ( NPPV ) receive within past 6 week prior inform consent 8 . Subjects history tracheotomy severe pharyngeal nasal cavity surgery within past 6 month 9 . Pregnant woman 10 . Subjects cognitive impairment mental disorder regard investigator inadequate evaluate study 11 . Subjects regard investigator unable operate myAIRVO2 adequately home 12 . Subjects participate wil participate another clinical trial time inform consent 13 . Any case regard investigator inadequate enrollment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>myAIRVO2</keyword>
	<keyword>high-flow nasal cannula therapy</keyword>
	<keyword>home oxygen therapy</keyword>
	<keyword>HOT</keyword>
</DOC>